ABSTRACT

Background

To estimate the health economic consequences of the recently introduced PPSV23 vaccination programme for persons aged 65+ in Denmark and of a potential extension of the programme to include persons aged 60–64 years.

Research design and methods

A Markov model was adapted to the Danish healthcare setting to simulate the epidemiological and economic burden of invasive pneumococcal disease and non-bacteremic pneumococcal pneumonia using information from published sources and Danish databases.

Results

We found that the recent introduction of an age-based vaccination programme offering PPSV23 vaccination to the population of persons aged 65+ in Denmark will lead to a societal gain of EUR 72.0 million and prevent 19,707 cases of pneumococcal disease and 1,308 deaths per 1 million persons during the five-year study period.

Similarly, we estimate that extending the programme to include persons aged 60–64 will lead to a gain of EUR 14.6 million per 1 million persons and prevent an additional 6,223 cases of pneumococcal disease and 185 deaths.

Conclusion

The recent introduction of the age-based vaccination programme offering PPSV23 vaccination to all persons aged 65+ in Denmark is cost-effective. This is also the case if the programme is extended to include persons aged 60–64.

中文翻译：

---

向 65 岁及以上的成年人引入基于 PPSV23 的疫苗接种计划的健康经济评估，以及丹麦 60-64 岁年龄组的扩展

摘要

背景

评估最近在丹麦推出的针对 65 岁以上人群的 PPSV23 疫苗接种计划的健康经济后果，以及该计划可能扩展到包括 60-64 岁人群的健康经济后果。

研究设计与方法

马尔可夫模型适用于丹麦的医疗保健环境，使用来自已发布来源和丹麦数据库的信息来模拟侵袭性肺炎球菌病和非菌性肺炎球菌性肺炎的流行病学和经济负担。

结果

我们发现，最近在丹麦推出了一项为 65 岁以上人群提供 PPSV23 疫苗的基于年龄的疫苗接种计划，这将带来 7200 万欧元的社会收益，每 100 万人中预防 19,707 例肺炎球菌病和 1,308 例死亡在五年的学习期间。

同样，我们估计将计划扩大到 60-64 岁的人群将导致每 100 万人获得 1460 万欧元的收益，并防止额外的 6,223 例肺炎球菌病病例和 185 例死亡。

结论

最近推出的基于年龄的疫苗接种计划为丹麦所有 65 岁以上的人提供 PPSV23 疫苗接种是具有成本效益的。如果该计划扩大到包括 60-64 岁的人，情况也是如此。